Support teaching, research, and patient care.
Gynecologic MalignanciesImmunotherapyBiologic Response ModifiersNew Drug DevelopmentAntigenic specificities of human antibodies encoded by the VH4-34 gene
Phase II/III Trametinib in Recurrent or Progressive Ovarian Cancer or Peritoneal Cancer Not Recruiting
This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Madelyn Gutierrez Gomez, 650-723-0298 .
View full details
Phase II/III Paclitaxel/Carboplatin +/- Metformin in Stage III, IV or Recurrent Endometrial Cancer Not Recruiting
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help paclitaxel and carboplatin work better by making cancer cells more sensitive to the drugs. It is not yet known whether paclitaxel and carboplatin is more effective with or without metformin hydrochloride in treating endometrial cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Suzanne Friedrich, 650-725-0436.
Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer Not Recruiting
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer. Learning about the side effects of chemotherapy in older patients may help doctors plan better ways to treat cancer.
Stanford is currently not accepting patients for this trial. For more information, please contact Sharanya Ramasubramanian, 650-723-0622.
Phase II (Paclitaxel and Carboplatin) +/- MK-1775 in Platinum Sensitive p53 Mutant Ovarian Cancer Not Recruiting
This is a study of the safety and efficacy of adavosertib in combination with paclitaxel plus carboplatin in the treatment of ovarian, fallopian tube, and primary peritoneal tumors with the P53 mutation. In Part 1, a small group of participants will receive adavosertib along with paclitaxel plus carboplatin to establish the tolerability of adavosertib with this combination. In Part 2, participants will be randomly assigned to receive either adavosertib plus paclitaxel and carboplatin OR placebo plus paclitaxel and carboplatin to assess efficacy of adavosertib compared to placebo. The primary hypothesis of the study (Part 2) is that administration of adavosertib in combination with paclitaxel plus carboplatin in participants with platinum sensitive p53 mutant ovarian cancer will result in improvement in progression free survival (PFS) per enhanced Response Evaluation Criteria In Solid Tumors version 1.1 (enhanced RECIST 1.1) compared to participants treated with paclitaxel plus carboplatin alone.
Stanford is currently not accepting patients for this trial. For more information, please contact Kashif Naseem, 650724-3155.
Phase Ib OMP-54F28 in Combo w/ Paclitaxel & Carboplatin in Recurrent Platinum-Sensitive Ovarian CA Not Recruiting
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with paclitaxel and carboplatin. OMP-54F28 will be administered IV on Days 1 of each 21-day cycle. Paclitaxel (175 mg/m2) and carboplatin (AUC = 5 mg/mL • min) will be administered IV on Day 1 of each cycle. A total of 6 cycles of paclitaxel and carboplatin will be given. Additional cycles may be given as per institutional standard of care after discussion with the Medical Monitor. Treatment with OMP-54F28 will continue after completion of treatment with paclitaxel and carboplatin. The planned dose levels of OMP-54F28 are 5 and 10 mg/kg.
Stanford is currently not accepting patients for this trial. For more information, please contact Ashley Powell, 650-724-3308.
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia Not Recruiting
A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety, pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with vincristine.
Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
Phase II Step Into Wellness: A Program of Health and Recovery for Endometrial Cancer Survivors Not Recruiting
This randomized phase II trial studies how well a health and recovery program works in increasing physical activity level in stage IA-IIIA endometrial cancer survivors. Health and recovery program which includes exercise counseling, Fitbit tracker, and phone or email/text communication may increase the level of physical activity in endometrial cancer survivors and promote and maintain behavior change at a lower cost.
Stanford is currently not accepting patients for this trial. For more information, please contact Melissa Usoz, 650-723-8843.
Phase II Oregovomab (Antibody) Plus Chemotherapy in New Dx Advanced Ovarian Cancer Not Recruiting
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Phase II Rucaparib in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Recruiting
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
Stanford is currently not accepting patients for this trial. For more information, please contact Alma Gonzalez, 650-498-0624.
Phase III Paclitaxel + AMG 386 or Placebo in Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Not Recruiting
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Stanford is currently not accepting patients for this trial. For more information, please contact Maureen Sutton, 6507259167.
Overcoming Obstacles to Clinical Trials Enrollment through a Navigator Program Not Recruiting
Pilot study for assessing the effectiveness of a Navigator program to aid in clinical trial participation amongst the Chinese demographic
Stanford is currently not accepting patients for this trial. For more information, please contact Mei-Chin Kuo, 6507361977.
Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer Not Recruiting
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cervical cancer patients. We believe that some of these markers may be useful in selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.
Stanford is currently not accepting patients for this trial. For more information, please contact Dylann Fujimoto, 650-723-8843.
Phase II Maintenance Tx w/ MUC1 Dendritic Cell Vaccine(Cvac) in Epithelial Ovarian CA in Remission Not Recruiting
As \< 10% of the necessary patients required by the protocol were recruited and the data were not intended to support a labeling claim, it was determined that the abbreviated clinical study report (CSR) was the appropriate reporting format. No efficacy analyses were performed as the trial was terminated early with incomplete enrollment of \< 10%. The purpose of this study is to determine if an investigational cell therapy called Cvac can help epithelial ovarian cancer (EOC) from returning when administered to patients who are in complete remission after surgical removal of their tumor followed by standard first-line (Part A) or second-line (Part B) chemotherapy. Following remission, patients will undergo leukapheresis for the manufacture of the study agent. After completion of chemotherapy and confirmation of remission, patients will enter the treatment phase of the study.
Stanford is currently not accepting patients for this trial. For more information, please contact Kashif Naseem, 650-724-3155.
Phase III Olaparib Maintenance Monotherapy in BRCA Mutated Adv (FIGO Stg III-IV) Ovarian Cancer Not Recruiting
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
Stanford is currently not accepting patients for this trial. For more information, please contact Suzanne Friedrich, 650-725-0426.
Phase IB HGS1036 in Combination With Chemotherapy in Advanced Solid Malignancies
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.
Phase III Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Plat Resistant Ovarian Ca Not Recruiting
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).
Stanford is currently not accepting patients for this trial. For more information, please contact Aarti Kale, 650-723-0622.
Phase II ACP-196 Alone and in Combination with Pembrolizumab in Recurrent Ovarian Cancer Not Recruiting
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
